companies

T-knife Therapeutics

Founded 2018
Employees 70+
Primary contact
Robert-Rössle-Straße 10
13125 Berlin
Germany
+49-30-94892432
Links
https://www.t-knife.com/
Diseases & Conditions
Sections
T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients. The company leverages its proprietary humanized T-cell receptor (HuTCR) mouse platform to produce fully human TCRs, naturally selected in vivo for optimal affinity and specificity. T-knife is developing a pipeline of potential first/best-in-class TCR therapeutics against targets with high unmet medical need, including cancer testis antigens, viral antigens and commonly shared neoantigens. In addition to Berlin, the company also has an office in San Francisco.
Founded 2018
Employees 70+
Primary contact
Robert-Rössle-Straße 10
13125 Berlin
Germany
+49-30-94892432
Links
https://www.t-knife.com/
Diseases & Conditions
Sections

Funding 💰

Total $197.4M
Select investors RA Capital Management, Versant Ventures, Fidelity Management and Research Company, Andera Partners, Boehringer Ingelheim Venture Fund, EQT Life Sciences, Casdin Capital, Qatar Investment Authority

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • TCR therapies for solid tumors: Through the use of natural, fully human TCRs, T-knife's product candidates are designed to induce an organically optimized immune signaling cascade intended to stimulate a potent T cell-driven immune response. The company's TCR therapies target tumor-specific antigens in multiple, difficult-to-treat solid tumor indications.
  • Pipeline: T-knife is advancing a proprietary portfolio of TCR-T product candidates, for which the company retains worldwide commercial rights. 🔗
  • Founded by experts: The company was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité University Hospital in Berlin.

Video ▶️

Quotes 💬

“
T-knife has an elegant and differentiated approach to identifying potent, cancer-specific TCRs with naturally optimized affinity and specificity profiles, creating a next-generation platform for this promising therapeutic field. We are pleased to be progressing TK-8001 toward the clinic and to advance our broader portfolio of product candidates.
— Alex Mayweg, Chairman of T-knife and Managing Director at Versant Ventures 🔗
“
The field of TCR-T holds significant promise to change the treatment paradigm for many cancer patients. We are highly encouraged by the progress being made at T-knife to advance its important next-generation therapies.
— Karin Kleinhans, PhD, Partner at LSP 🔗
“
As a founding investor, it is gratifying to witness the continued success at T-knife. The completion of the Series B financing is an important milestone that will enable us to execute on our vision of building a leading transatlantic immuno-oncology company.
— Olivier Litzka, Partner at Andera Partners 🔗
Last update: June 4, 2023